223 related articles for article (PubMed ID: 8302286)
1. Conformational and biological studies of neuropeptide Y analogs containing structural alterations.
Fournier A; Gagnon D; Quirion R; Cadieux A; Dumont Y; Pheng LH; St-Pierre S
Mol Pharmacol; 1994 Jan; 45(1):93-101. PubMed ID: 8302286
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of truncated neuropeptide Y analogues with modifications of the tyrosine residue in position 1 on Y1, Y2 and Y3 receptor sub-types.
Dumont Y; Satoh H; Cadieux A; Taoudi-Benchekroun M; Pheng LH; St-Pierre S; Fournier A; Quirion R
Eur J Pharmacol; 1993 Jul; 238(1):37-45. PubMed ID: 8405081
[TBL] [Abstract][Full Text] [Related]
3. Ligand binding and functional effects of systematic double D-amino acid residue substituted neuropeptide Y analogs on Y1 and Y2 receptor types.
Grundemar L; Kahl U; Callréus T; Langel U; Bienert M; Beyermann M
Regul Pept; 1996 Apr; 62(2-3):131-6. PubMed ID: 8795076
[TBL] [Abstract][Full Text] [Related]
4. Comparative structural requirements of brain neuropeptide Y binding sites and vas deferens neuropeptide Y receptors.
Martel JC; Fournier A; St-Pierre S; Dumont Y; Forest M; Quirion R
Mol Pharmacol; 1990 Oct; 38(4):494-502. PubMed ID: 2172766
[TBL] [Abstract][Full Text] [Related]
5. Alpha-helical small molecular size analogues of neuropeptide Y: structure-activity relationships.
Jung G; Beck-Sickinger AG; Dürr H; Gaida W; Schnorrenberg G
Biopolymers; 1991 May; 31(6):613-9. PubMed ID: 1657233
[TBL] [Abstract][Full Text] [Related]
6. Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous systems: BIB03304 (Y1) and CGP71683A (Y5).
Dumont Y; Cadieux A; Doods H; Fournier A; Quirion R
Can J Physiol Pharmacol; 2000 Feb; 78(2):116-25. PubMed ID: 10737674
[TBL] [Abstract][Full Text] [Related]
7. Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacy.
Michel MC; Gaida W; Beck-Sickinger AG; Wieland HA; Doods H; Dürr H; Jung G; Schnorrenberg G
Mol Pharmacol; 1992 Oct; 42(4):642-8. PubMed ID: 1331755
[TBL] [Abstract][Full Text] [Related]
8. Stabilization of alpha-helix in C-terminal fragments of neuropeptide Y.
Yumoto N; Murase S; Hattori T; Yamamoto H; Tatsu Y; Yoshikawa S
Biochem Biophys Res Commun; 1993 Nov; 196(3):1490-5. PubMed ID: 8250906
[TBL] [Abstract][Full Text] [Related]
9. Antagonistic properties of centrally truncated analogs of [D-Trp(32)]NPY.
Balasubramaniam A; Ujhelyi M; Borchers M; Huang Y; Zhai W; Zhou Y; Johnson M; Sheriff S; Fischer JE
J Med Chem; 1996 Mar; 39(5):1142-7. PubMed ID: 8676351
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.
Doods HN; Wienen W; Entzeroth M; Rudolf K; Eberlein W; Engel W; Wieland HA
J Pharmacol Exp Ther; 1995 Oct; 275(1):136-42. PubMed ID: 7562541
[TBL] [Abstract][Full Text] [Related]
11. Structure and dynamics of micelle-bound neuropeptide Y: comparison with unligated NPY and implications for receptor selection.
Bader R; Bettio A; Beck-Sickinger AG; Zerbe O
J Mol Biol; 2001 Jan; 305(2):307-29. PubMed ID: 11124908
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships of neuropeptide Y analogues with respect to Y1 and Y2 receptors.
Beck-Sickinger AG; Jung G
Biopolymers; 1995; 37(2):123-42. PubMed ID: 7893945
[TBL] [Abstract][Full Text] [Related]
13. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
Wieland HA; Willim KD; Entzeroth M; Wienen W; Rudolf K; Eberlein W; Engel W; Doods HN
J Pharmacol Exp Ther; 1995 Oct; 275(1):143-9. PubMed ID: 7562543
[TBL] [Abstract][Full Text] [Related]
14. Structural similarities of micelle-bound peptide YY (PYY) and neuropeptide Y (NPY) are related to their affinity profiles at the Y receptors.
Lerch M; Mayrhofer M; Zerbe O
J Mol Biol; 2004 Jun; 339(5):1153-68. PubMed ID: 15178255
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP.
Dumont Y; Thakur M; Beck-Sickinger A; Fournier A; Quirion R
Neuropeptides; 2004 Aug; 38(4):163-74. PubMed ID: 15337369
[TBL] [Abstract][Full Text] [Related]
16. Conformational analysis of neuropeptide Y segments by CD, NMR spectroscopy and restrained molecular dynamics.
Gurrath M; Bisello A; Bottazzo K; Chung CW; Mammi S; Peggion E
J Pept Sci; 1996; 2(3):176-93. PubMed ID: 9231326
[TBL] [Abstract][Full Text] [Related]
17. The contribution of helical potential to the in vitro receptor binding activity of a neuropeptide Y N-terminal deletion fragment.
Doughty MB; Hu L
Biopolymers; 1993 Aug; 33(8):1195-206. PubMed ID: 8364154
[TBL] [Abstract][Full Text] [Related]
18. Activation of neuropeptide Y1 and neuropeptide Y2 receptors by substituted and truncated neuropeptide Y analogs: identification of signal epitopes.
Grundemar L; Krstenansky JL; Håkanson R
Eur J Pharmacol; 1993 Mar; 232(2-3):271-8. PubMed ID: 8467862
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family.
Cabrele C; Beck-Sickinger AG
J Pept Sci; 2000 Mar; 6(3):97-122. PubMed ID: 10759209
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the peptide binding requirements for the cloned human pancreatic polypeptide-preferring receptor.
Gehlert DR; Schober DA; Beavers L; Gadski R; Hoffman JA; Smiley DL; Chance RE; Lundell I; Larhammar D
Mol Pharmacol; 1996 Jul; 50(1):112-8. PubMed ID: 8700103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
